<DOC>
	<DOCNO>NCT00812994</DOCNO>
	<brief_summary>Study intend determine baseline difference serum neurosteroid level neurotrophic factor ( BDNF ) level healthy control vs unmedicated depressed subject , whether level change antidepressant treatment . Study also intend determine baseline neurosteroid/ BDNF level , change level =treatment , correlate clinical antidepressant response escitalopram ( Lexapro ) .</brief_summary>
	<brief_title>Neurotrophic Factors Depression</brief_title>
	<detailed_description>The study approve UCSF Committee Human Research , participant give inform consent . The depressed subject begin treatment placebo one week , follow escitalopram eight week ( 10 mg per day x 4 week , follow 20 mg per day x 4 week , tolerate ) double-blind , fixed-order , within-subject cross-over manner . The depressed subject psychiatric rater unaware study design sequence duration treatment . Depressed control subject underwent venipuncture obtain blood assay . The control underwent venipuncture , depressed subject venipuncture prior begin active escitalopram treatment 8 week escitalopram treatment . Blood also collect Weeks 4 8 treatment depressed subject assay citalopram citalopram metabolite , gauge medication compliance . Finally , depression severity global clinical change assess depressed subject Baseline end Week 8 escitalopram treatment .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Male subject unipolar Major Depressive Disorder ( DSMIV ) minimum score 22 10item Montgomery√Ösberg Depression Rating Scale ( MADRS ) medicationfree least 6 week , enrol . Fifteen individually agematched ( + 3 year ) healthy male control history psychiatric illness also enrol . Subjects ' age range 22 55 y.o . ( mean + S.D.= 41.4 + 8.75 y.o. ) . All subject require pas urine toxicology screen ( assess presence drug abuse ) day test . Individuals comorbid panic disorder exclude , since may poorly tolerate typical start dos antidepressant , individual comorbid posttraumatic stress disorder exclude , since may neuroendocrine regulatory response different depressed subject without PTSD . Exclusion criterion group include recent ( within 6 month ) alcohol drug abuse define DSMIV criterion , concurrent psychotherapeutic intervention , poor medical health abnormal clinical lab , active suicidality , use medication could interfere study .</criteria>
	<gender>Male</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Depression</keyword>
	<keyword>BDNF</keyword>
	<keyword>neurotrophic factor</keyword>
	<keyword>neurosetroid</keyword>
	<keyword>allopregnanolone</keyword>
</DOC>